Analyst questions the bigger picture for GILD, including risks and visibility challenges wavering in 2018.
Gilead is very confident on the successful commercial launch of Axi-Cel.
Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu
How Do Biotech’s Movers and Shakers Fare Under Puravida Funds’ Healthcare-Centric Trading Strategy?
Gilead Pivots to Cell Therapy; Cowen’s Phil Nadeau Weighs in
How Has a Deal Between Kite and Gilead Likewise Sent Juno Shares Jumping?
Synergy Still Showcases Promising Commercial Trajectory in CIC Rodman & Renshaw analyst Ram Selvaraju still looks for momentum in Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) chronic idiopathic …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the FDA has granted priority review for the company’s New Drug Application (NDA) for an investigational, fixed-dose combination …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the FDA has approved updated labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the European Commission has granted marketing authorization for Vosevi® (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily single …
